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Abstract: Squamous cell carcinoma of the head and neck (SCCHN) presents at a locally 
advanced (LA) stage in many patients. Chemotherapy has been successfully integrated into 
ﬁ  rst-line treatment programs, either during or prior to radiotherapy (RT) – the cornerstone 
modality for local disease control of inoperable disease or when organ preservation is desired. 
Concomitant chemoradiotherapy (CCRT) provides an absolute survival beneﬁ  t when compared 
with other types of locoregional therapy that exclude chemotherapy. Nonetheless, distant metas-
tases still represent the most common cause of treatment failure. Consequently, adding induction 
chemotherapy (ICT) to deﬁ  nitive non-surgical local therapies with a curative intent has been 
vigorously explored in LA SCCHN. Recently, it has been shown that ICT using the combination 
of the taxane docetaxel with cisplatin–5-ﬂ  uorouracil provides signiﬁ  cant survival beneﬁ  t over 
cisplatin–5-FU, when used before either deﬁ  nitive RT (TAX323 trial) or carboplatin-based CCRT 
(TAX324 trial). Docetaxel is also being investigated in metastatic or recurrent (M/R) disease, 
with promising initial results. It is very likely that the future management strategies of SCCHN 
will incorporate biologic agents as an add-on to docetaxel-containing schemas, administered 
either as ICT prior to CCRT in the LA setting or for the management of M/R disease.
Keywords: chemoradiotherapy, chemotherapy, docetaxel, head and neck carcinoma, induc-
tion, locally advanced, taxane
Introduction
With a global annual incidence of approximately 500,000 cases, squamous cell 
carcinoma of the head and neck (SCCHN) – which includes carcinomas of the oral 
cavity, ﬂ  oor of mouth, tongue, tonsils and juxtatonsillar fossae, larynx, and pharynx 
(oropharynx, epipharynx, and hypopharynx) – is the ﬁ  fth most common cancer 
worldwide (Parkin et al 2005). Even in the US, where the incidence of SCCHN is 
relatively low, this type of cancer accounts for up to 3% of all malignant neoplasms 
(National Cancer Institute 2008a). SCCHN, an aggressive epithelial malignancy, has 
historically been associated with poor prognosis. Moreover, as the majority of SCCHN 
cases are associated with tobacco consumption and alcohol abuse, many patients 
present with notable comorbidities linked to lifestyle, a factor that limits the delivery 
of effective antitumor therapy. Indeed, up until the mid-1990s, 5-year survival rates 
had been reported to be as low as 30% or below for stage IVa/b (M0) disease (Vokes 
et al 1993), and 40% for stage III disease (Laramore et al 1992). However, over the 
last decade, overall mortality rates for cancers of the oral cavity, pharynx, and larynx 
have been modestly decreasing in the general population (National Cancer Institute 
2008b, c). This is the case not only in low stage cancers, an effect mostly attributable to 
progressively earlier detection of curable tumors over time, but also in locally advanced 
(LA) disease. The latter effect is due to an interplay of numerous factors, including 
the continuous advances in oncologic supportive care, reﬁ  nement of the manner of 
administration of complex chemotherapy regimens, technical advances in the delivery Therapeutics and Clinical Risk Management 2008:4(5) 866
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of radiotherapy, optimization of surgical techniques (applied 
either in the primary or salvage setting), and last, but not least, 
an increased acceptance of the value of a multidisciplinary 
approach in the management of this disease. At this point, we 
believe that “state-of-the-art” delivery of aggressive therapy 
could potentially lead to 5-year survival rates in the range of 
35% to 37% for stage IVa/b (M0) disease, and 44% to 46% 
for stage III disease. The above notwithstanding, the great 
effort behind these modest increases in survival continues 
to largely reﬂ  ect the adverse biological determinants of this 
malignancy. These factors result in an overall aggressive 
clinical phenotype, ie, the frequent presence of locoregion-
ally advanced disease at the time of initial presentation, 
as well as unfavorable patterns – or timing – of treatment 
failure in patients who eventually develop metastatic or 
recurrent (M/R) disease or second primary carcinomas of 
the upper aerodigestive tract and lung (Seiwert and Cohen 
2005). Finally, it has been noted that even nowadays, and 
despite optimal delivery of curative-intent therapy for LA 
SCCHN, traditional approaches aiming at both excellent 
locoregional control and ultimate disease eradication can 
often be debilitating and occasionally disﬁ  guring, and can 
lead to long-term devastating consequences for quality of life 
(eg, life-long enteral tube use for alimentation). Therefore, 
fostering further improvements in the methods of delivery 
of a complex multimodal treatment “package” is extremely 
important, especially if such an improvement could result 
in a signiﬁ  cant decrease in the intensity of application of 
locoregional therapy, which remains the major cause for 
most of the irreversible and incapacitating side effects of 
currently applied treatment plans.
In the current Union Internationale Contre le Cancer/
American Joint Committee on Cancer (UICC/AJCC) staging 
system, stages III, IVa, and IVb comprise “LA SCCHN 
(M0)”, and in contrast to other epithelial malignancies, only 
stage IVc is associated with distant metastatic (M1) disease 
(Greene et al 2002; Irish and Lee 2005). Patient outcomes 
have improved over the past 3 decades as a result of several 
advances, which include (among others): a) stepwise 
improvements in the concept of multimodality therapy (con-
sisting of increasingly sophisticated combinations of surgery, 
radiotherapy [RT], and chemotherapy); b) application of 
technically expert single-modality therapy (when the latter is 
appropriately chosen in selected patients [eg hyperfractionated 
RT in stage III oropharyngeal carcinoma]); c) individual 
technical innovations within each discipline (eg the advent of 
intensity modulated or image-guided radiation therapy); and 
d) intensiﬁ  cation of ancillary care methods (such as speech 
therapy or nutritional support) (Miller 1990; Nelson 1998; 
Vokes 2005). However, successful treatment with curative 
intent of both LA and M/R SCCHN remains a formidable 
clinical challenge, and new treatment options and approaches 
are urgently needed. This is especially true for patients who 
are either not eligible for surgery, have low surgical curability 
rates, or harbor tumors for which non-surgical therapy rep-
resents a more acceptable – and arguably better – treatment 
(eg, RT or chemoradiotherapy for inﬁ  ltrative LA tonsillar 
carcinomas). For all the above SCCHN patients, the combina-
tion of RT and cytotoxic chemotherapy, and more recently 
biologically targeted agents, has been the focus of intense 
clinical investigation, resulting in the launch of several 
important clinical trials.
To this end, this review presents an in-depth summary 
of novel data in the context of both treatment of LA disease 
(ﬁ  rst-line) and management of recurrent (second-line) or 
metastatic disease (mainly ﬁ  rst-line). Focus is given to the 
incorporation of the taxane, docetaxel, in the chemotherapy 
component of clinical treatment programs in an effort to 
maximize patient beneﬁ  t.
Chemotherapy regimens used 
for the treatment of locally 
advanced SCCHN
Generalities
The integration of cytotoxic chemotherapy in the treatment 
of SCCHN has been the subject of clinical investigation for 
more than 3 decades. For example, when surgery is the chosen 
primary curative-intent therapy in patients with “resectable” 
LA SCCHN, single-agent or combination chemotherapy 
has been applied in both the preoperative (neoadjuvant or 
induction) and postoperative (adjuvant) settings. In the latter 
context, chemotherapy is generally used in combination 
with deﬁ  nitive postoperative RT (PORT), ie, postoperative 
chemoradiotherapy. Similarly, signiﬁ  cant progress has been 
witnessed toward the integration of chemotherapy in clinical 
treatment programs for LA SCCHN in patients who are not 
surgical candidates, and in whom RT – as the cornerstone 
modality for local control – plays a major role toward achieving 
complete disease eradication. In the latter realm, cytotoxic 
chemotherapy can be administered during RT (ie, concomitant 
chemoradiotherapy [CCRT]) or can be used prior to RT (ie 
induction chemotherapy [ICT]). A novel treatment paradigm 
in LA disease is sequential therapy, in which ICT is followed 
by CCRT, in a sequence that may also include surgery for 
either exstirpation of residual/recurrent disease at the primary Therapeutics and Clinical Risk Management 2008:4(5) 867
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site and/or regional nodal territories (surgical salvage) or, in 
the context of preplanned neck dissection, conﬁ  rmation of 
pathologic complete response (pCR) in patients with bulky 
regional lymphadenopathy (stage T × N2) at presentation. 
In the subsequent sections of this review, we will focus on 
the impact of chemotherapy in SCCHN patients who are not 
surgical candidates or who desire organ preservation (when 
the latter is realistically possible).
Several studies have shown that the exact manner of 
integrating a chemotherapy regimen with deﬁ  nitive RT has 
a signiﬁ  cant bearing on overall survival (OS) of patients 
with LA SCCHN. In general, CCRT has been associated 
with a greater survival beneﬁ  t than ICT treatment regimens, 
and the magnitude of this beneﬁ  t has been dependent on the 
speciﬁ  c drug – or drug combination – used (Pignon et al 
2000). This difference in treatment beneﬁ  t in LA disease 
was shown by a large meta-analysis, which used updated 
individual patient data published by the investigators of the 
French Meta-analysis of Chemotherapy in Head and Neck 
Cancer (MACH-NC) group. Locoregional treatment (RT and/
or surgery) and locoregional treatment plus chemotherapy 
(delivered as either ICT or concomitantly with RT) were 
compared in terms of OS (Pignon et al 2000). The timing of 
chemotherapy was found to have a major effect on 5-year 
absolute survival benefit. Overall, ICT regimens were 
associated with no signiﬁ  cant beneﬁ  t compared with control 
regimens (locoregional deﬁ  nitive therapy upfront), although 
when the combination of cisplatin and 5-ﬂ  uorouracil (PF) 
was given for ICT, there was a 5% absolute survival beneﬁ  t. 
In this meta-analysis, CCRT resulted in a signiﬁ  cant absolute 
survival rate beneﬁ  t of 8% at 5 years (Pignon et al 2000). It 
should be noted at this point that ICT is not ﬁ  rmly established 
as part of the management plan speciﬁ  cally for LA squamous 
cell carcinoma of the oral cavity; radical surgical exstirpation 
of the primary tumor (typically followed by either PORT or 
postoperative CCRT) remains the therapy of choice in oper-
able patients, and upfront CCRT is still widely employed in 
inoperable cases. The Pignon meta-analysis results represent 
a signiﬁ  cant part of the scientiﬁ  c basis for the broad adoption 
of CCRT (especially RT combined with high-dose 3-weekly 
cisplatin) in clinical practice for the treatment of LA SCCHN 
in North America. In the speciﬁ  c context of maintenance of 
an anatomically intact larynx, CCRT has also been strongly 
advocated as the most successful strategy for non-operative 
larynx preservation, according to the published results 
of the Radiation Therapy Oncology Group 91–11 trial in 
which larynx preservation – rather than laryngectomy-free 
survival – was the primary endpoint (Forastiere et al 2003). 
In the next section, the role of ICT followed by deﬁ  nitive 
locoregional, non-surgical therapy in the management of 
LA SCCHN will be discussed and juxtaposed to the CCRT 
treatment paradigm; once again, we will focus on the impact 
of incorporating docetaxel in the ICT portion of clinical 
treatment programs.
Docetaxel use in locally advanced disease
Over time, and along with the improved survival and 
locoregional control (LRC) achievable with the aforemen-
tioned schedules of CCRT delivery, a shift in the patterns 
of treatment failure has been observed. Historically, LRC 
represented the most important concern in LA SCCHN 
management, in that the occurrence of distant metastases 
(DMs) was relatively less common. However, increasingly 
sophisticated delivery of CCRT has led to LRC rates in 
excess of 90% and the emergence of DMs as the most fre-
quent cause of treatment failure (Vokes et al 2000; Adelstein 
et al 2002). This observation suggested a possible role for 
adding further elements of systemic chemotherapy to the 
entire treatment “package” with the aim of improving global 
treatment success measures by decreasing the incidence of 
distal recurrence (Adelstein and Leblanc 2006). In view of the 
above issues, signiﬁ  cant interest in adding ICT to deﬁ  nitive 
non-surgical local therapies has recently resurged.
Assuming ICT is selected for the upfront treatment of 
LA SCCHN (to be followed by local deﬁ  nitive therapy), a 
long-honored standard approach has been to deliver cisplatin 
and 5-ﬂ  uorouracil (5-FU) (the PF doublet). The PF regimen 
was initially championed by Al-Sarraf et al (1998) as a highly 
active regimen against advanced nasopharyngeal carcinoma 
(NPC) when used as “consolidation” after CCRT, ie, in an 
adjuvant rather than an induction/neoadjuvant approach, 
as was the case in the seminal Intergroup (INT)-0099 trial. 
The use of the PF regimen was further reﬁ  ned during the 
next 2 decades, leading to its widespread use for the manage-
ment of not only NPC, but progressively of LA SCCHN. PF 
ICT was especially favored in Latin Europe (France, Italy, 
and Spain), but was also used in parts of South America and 
East Asia, where it was accepted as a standard ICT regimen 
by many oncologists, who would consider its use in many 
patients, while other patients would receive upfront cisplatin-
containing CCRT (Lefebvre and Bonneterre 1996; Seiwert 
and Cohen 2005).
In ICT early clinical trials, despite overall response rates 
(ORRs) and complete response (CR) rates as high as 90% 
and 50%, respectively, no consistent improvement in LRC 
or survival was demonstrated (Adelstein and Leblanc 2006). Therapeutics and Clinical Risk Management 2008:4(5) 868
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It is of note, however, that in several of these ICT trials, 
DMs were indeed reduced among patients who received 
chemotherapy (Schuller et al 1988; Department of Veterans 
Affairs Laryngeal Cancer Study Group 1991; Paccagnella 
et al 1994). The lack of impact of this ICT-related reduction 
in DMs on OS was subsequently attributed to the historically 
limited importance of distant vs locoregional failure and the 
accompanying disease recognition and reporting bias. More 
recently, the taxanes – paclitaxel, but also docetaxel – have 
shown promising initial activity in various preliminary clini-
cal studies in SCCHN patients, in both locally advanced and 
disseminated/recurrent settings. Consequently, over the last 
few years, several investigators have addressed the effect 
of adding taxanes to PF-based ICT in order to increase the 
efﬁ  cacy of the PF doublet and improve OS in patients with 
LA SCCHN (Hitt et al 2002, 2005; Posner and Lefebvre 
2003; Fountzilas et al 2005a; Rapidis et al 2006; Posner et al 
2007; Vermorken et al 2007).
In a randomized phase III study of 382 patients with LA 
head and neck cancer, ICT comprising paclitaxel in addi-
tion to cisplatin and 5-FU (Pacli-PF) – followed by cisplatin 
CCRT – achieved a higher response rate (RR), increased time 
to treatment failure, and was better tolerated than ICT with PF 
alone (Hitt et al 2005). Patients received either PF (cisplatin 
100 mg/m2 Day 1 plus 5-FU 1000 mg/m2 continuous infusion 
on Days 1–5) or Pacli-PF (paclitaxel 175 mg/m2 Day 1, 
cisplatin 100 mg/m2 Day 2 and 5-FU 500 mg/m2 continuous 
infusion on Days 2–6) for 3 cycles every 21 days. Additional 
CCRT with cisplatin (100 mg/m2 Days 1, 22, and 43) and 
RT (70 Gy) was administered to patients with a CR or partial 
response (PR), 80% in the primary tumor site. A CR was 
observed in 33% of patients in the Pacli-PF arm vs 14% in 
the PF arm (p  0.001); median time to treatment failure 
(TTF) was 20 months vs 12 months (log-rank p = 0.006) in 
the Pacli-PF and PF arms, respectively, and median OS was 
43 months vs 37 months, respectively (log-rank p  0.06). 
The overall incidence of acute grade 3/4 adverse events 
(AEs) (Pacli-PF vs PF, respectively) was similar in the two 
treatment arms (60% vs 68%); however, compared with 
Pacli-PF, PF was associated with signiﬁ  cantly more grade 
2–4 mucositis (16% vs 53%) during ICT, grade 3/4 muco-
sitis (34% vs 55%) during CCRT, and grade 3/4 nausea and 
vomiting (4% vs 17%). Grade 3/4 neutropenia was more 
common with Pacli-PF than PF (32% vs 20%).
Although the above study by Hitt and colleagues 
demonstrated the feasibility of delivering the Pacli-PF 
ICT combination prior to cisplatin-CCRT, the relative 
dearth of antecedent experience with paclitaxel-based 
induction regimens in the management of LA head and neck 
cancer is noteworthy, and deserves further comment here. 
Indeed, although early clinical (mainly phase I) data with 
Pacli-cisplatin ICT in LA SCCHN were reported as early 
as 1995 (Hitt et al 1995), the momentum in advancing the 
clinical development of paclitaxel-based regimens for ICT 
was not maintained, as evident by the 10-year period separat-
ing the aforementioned studies by Hitt’s group. Nevertheless, 
some interest in this regimen continues (Barone et al 2008). 
Similarly, the Pacli-PF triplet was not clinically studied to a 
signiﬁ  cant extent in a large cooperative group setting (either 
in the US or the EU) until the reporting in 2006 of efﬁ  cacy 
data in the metastatic (advanced) or recurrent – rather than 
LA – setting by the Head and Neck Working Group of the 
US Southwest Oncology Group (SWOG) (S0007 study) 
(Worden et al 2006). Moreover, the concept of paclitaxel-
based ICT has not been advanced in NPC since the mid 
1990s. Indeed, it was only in 2005 that preliminary efﬁ  cacy 
data were reported on the combination of cisplatin, epirubi-
cin, and paclitaxel (CEP) ICT followed by Pacli-CCRT in 
LA NPC, in a phase I/II study by the Hellenic Cooperative 
Oncology Group (HeCOG) (Fountzilas et al 2005b). The 
above situation with paclitaxel is in stark contrast with the 
wealth of data emanating from the clinical development of 
docetaxel in both SCCHN and NPC since the mid 1990s. 
Indeed, the integration of docetaxel in ICT schemas for 
both malignancies was promulgated by numerous clinical 
investigator groups, resulting in early reporting of impact-
ful phase II data on both efﬁ  cacy and deliverability of 
such schemas. One of these phase II studies focused on 
docetaxel (Taxotere®)–cisplatin–5-ﬂ  uorouracil (TPF) ICT 
in LA SCCHN; in this study, Posner et al (2001) reported a 
post-ICT overall response rate (complete response + partial 
response [CR + PR] of 93%, along with a pathologically 
conﬁ  rmed CR (pCR) of 92% in patients with clinical CR and 
54% in those with clinical PR. A second, conceptually similar 
phase II study in LA NPC patients by Glisson’s group dem-
onstrated that docetaxel-carboplatin (TCb) ICT followed by 
RT – or CCRT in a minority of cases – resulted in a post-ICT 
overall response rate of 89%, accompanied by estimated 
3-year progression-free survival (PFS) and OS rates of 54% 
and 74%, respectively (Johnson et al 2004). In view of the 
above, it becomes evident that docetaxel-containing regimens 
yielded more robust and abundant clinical data regarding the 
management of head and neck carcinoma than chemotherapy 
combinations containing paclitaxel.
One further comment is in order here regarding the 
different properties of the two clinically active taxanes in Therapeutics and Clinical Risk Management 2008:4(5) 869
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SCCHN, namely paclitaxel and docetaxel. Although both 
agents share a common mechanism of action involving 
tubulin polymer stabilization and cell-cycle arrest, 
docetaxel demonstrates a higher afﬁ  nity for β-tubulin, 
a longer intracellular half-life, as well as the ability to 
promote stabilization of microtubules at signiﬁ  cantly 
lower molar concentrations than paclitaxel (Schrijvers and 
Vermorken 2005). Although, in principle, both paclitaxel 
and docetaxel may be combined with PF to improve ICT 
efﬁ  cacy (Kies et al 2006), the potential for overlapping 
neuropathy with paclitaxel and cisplatin – especially when 
both agents are used at the higher end of their dosage range 
– has been recognized as potentially signiﬁ  cant. Further, 
the generally more predictable (and hence manageable) 
toxicity proﬁ  le of docetaxel compared with paclitaxel 
(when the latter is used at a higher dose range) has led 
to an increased interest in docetaxel-based therapy (Hitt 
et al 2006b).
The docetaxel–cisplatin–5-ﬂ  uorouracil 
(TPF) regimen
TPF as ICT prior to local/regional deﬁ  nitive therapy
Over the last decade, several phase I and II studies have 
investigated the combination of docetaxel with PF-based 
induction therapy (the TPF regimen) in patients with LA 
SCCHN (Table 1). Study results for this combination were 
encouraging, with high overall response rates (ORRs) 
(71%–100%) and promising long-term survival (62%–78% 
at 3 years) (Colevas et al 1998, 1999, 2002; Janinis et al 
2001; Posner et al 2001; Watanabe et al 2003; Schrijvers 
et al 2004; Tsukuda et al 2004). Following these results, 
a seminal phase III study was undertaken to assess the 
efﬁ  cacy and safety of TPF given as ICT prior to RT – the 
European Organisation for Research and Treatment of Cancer 
(EORTC) 24971/TAX 323 trial.
TPF followed by deﬁ  nitive RT: TAX 323
TAX 323 was a phase III trial that investigated TPF 
induction therapy followed by RT in patients with LA, 
unresectable SCCHN (Remenar et al 2006; Vermorken 
et al 2007). A total of 358 patients were enrolled, stratiﬁ  ed 
by primary disease site, and randomized to receive either 
TPF (docetaxel 75 mg/m2 and cisplatin 75 mg/m2 Day 1, 
plus 5-FU 750 mg/m2 Days 1–5, every 3 weeks for 4 cycles) 
or PF (cisplatin 100 mg/m2 Day 1 plus 5-FU 1000 mg/m2 
Days 1–5, every 3 weeks for 4 cycles). Following ICT, 
patients received conventional, accelerated, or hyperfrac-
tionated RT according to investigator or institutional choice, 
with surgery permitted either prior to RT, or at 3 months 
after completion of RT (depending on speciﬁ  c response 
thresholds). The study primary endpoint was PFS, with 
secondary endpoints of OS, tumor response, safety, and 
quality of life (QoL).
Compared with PF, ICT with TPF was associated with 
signiﬁ  cantly longer median PFS and OS (hazard ratios [HR] 
0.72 [95% conﬁ  dence interval {CI}: 0.56–0.93; p = 0.028] 
and 0.70 [95% CI: 0.55–0.89; p = 0.0042], respectively), 
while ORRs and CR rates (pre- and post-RT) were also 
significantly higher in the TPF group (Table 2). The 
tolerability proﬁ  le of the TPF regimen was deemed to be 
favorable. While the incidence of febrile neutropenia was 
higher with TPF, it was predictable based on the tolerability 
proﬁ  le of docetaxel and did not increase the incidence 
of treatment-related deaths (Table 2). The incidences of 
stomatitis/mucositis and thrombocytopenia were higher in 
the PF treatment arm than in the TPF arm, while the inci-
dences of leukopenia, neutropenia, and alopecia were lower. 
Dose reductions due to toxicity were more common in the 
PF treatment arm compared with the TPF arm (10.0% vs 
3.5%, respectively). In addition, the PF arm was associated 
with a higher incidence of dose delays (38.0% vs 2.0%, 
respectively), treatment discontinuations due to AEs (12.0% 
vs 6.0%, respectively), and deaths due to treatment-related 
toxicity (7.8% vs 3.7%, respectively). It is notable that with 
regard to mucosal local toxicity observed in TAX 323, the 
triplet TPF regimen was, overall, more tolerable than the 
PF regimen because of the signiﬁ  cantly reduced cumula-
tive dose of 5-FU in the TPF vs PF ICT regimen (15 g/m2 
vs 20 g/m2, respectively).
In addition to standard efﬁ  cacy endpoints, TAX 323 
compared the effect of TPF and PF on QoL indices. QoL was 
assessed using the EORTC QoL Global Health Questionnaire 
C30 (QLQ-C30) and the Performance Status Scale for Head 
and Neck patients (PSS-HN) standardized form. Patients 
receiving TPF had signiﬁ  cantly improved QLQ-C30 scores 
compared with those receiving PF (p = 0.01) and had a longer 
time to ﬁ  rst deterioration in World Health Organization (WHO) 
performance status (PS) (p = 0.0158). On the PSS-HN mea-
sure, TPF ICT was associated with signiﬁ  cant improvement 
in score for 3 key components of the scale – intake of normal 
diet (p = 0.0064), understandability of speech (p  0.0001), 
and ability to eat in public (p = 0.002).
TPF followed by CCRT: TAX 324
TAX 323 provided the basis for the use of docetaxel in 
the context of TPF ICT in combination with deﬁ  nitive Therapeutics and Clinical Risk Management 2008:4(5) 870
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Table 1 Docetaxel–cisplatin–5-ﬂ  uorouracil in phase I/II studies in squamous cell carcinoma of the head and neck
Reference Regimen Patients, n Complete RR, % ORR, % OS, %
1-year 2-year 3-year
Colevas et al 
(1998)
Docetaxel 25–60 mg/m2 D1 23 61 100 100 83 78
Cisplatin 25 mg/m2 D1-5
5-FU 700–800 mg/m2 D1-5
Leucovorin 500 mg/m2 D1-5
Colevas et al 
(1999)
Docetaxel 60 mg/m2 D1 30 63 93 83 80 77
Cisplatin 31.25 mg/m2 D1-4
5-FU 700–800 mg/m2 D1-4
Leucovorin 500 mg/m2 D1-4
Colevas et al 
(2002)
Docetaxel 60–95 mg/m2 D1 34 44 94 82 68 62
Cisplatin 100 mg/m2 D1
5-FU 700 mg/m2 D1-4
Leucovorin 500 mg/m2 D1-4
Posner et al 
(2001)
Docetaxel 75 mg/m2 D1 43 40 93 98 79 77
Cisplatin 100 mg/m2 D1
5-FU 1000 mg/m2 D1-4
Janinis et al 
(2001)
Docetaxel 80 mg/m2 D1 20 20 90 85 60 –
Cisplatin 40 mg/m2 D2-3
5-FU 1000 mg/m2 D1-3
Schrijvers 
et al (2004)
Docetaxel 75 mg/m2 D1 48 0 71 69 41 –
Cisplatin 75–100 mg/m2 D1
5-FU 750 mg/m2 D1-5
Tsukuda 
et al (2004)
Docetaxel 60–70 mg/m2 D1 18 22 94 – – –
Cisplatin 60–70 mg/m2 D4
5-FU 600–750 mg/m2 D1-5
Watanabe 
et al (2003)
Docetaxel 48 mg/m2 D1 34 59 88 – 93 –
Cisplatin 24 mg/m2 D1-4
5-FU 560 mg/m2 D1-5
Leucovorin 500 mg/m2 D1-4
Abbreviations: 5-FU, 5-ﬂ  uorouracil; ORR, overall response rate; OS, overall survival; RR, response rate.
RT. However, given the results of TAX 323, RT alone 
is no longer considered adequate treatment for LRC. As 
such, the efﬁ  cacy and tolerability of TPF ICT compared 
with standard PF was further investigated in a second 
large phase III trial, TAX 324, in which ICT was followed 
by carboplatin (Cb)-based CCRT (Posner et al 2007). In 
this multicenter, randomized trial, 501 patients with LA, 
histologically conﬁ  rmed SCCHN who had received no 
previous chemotherapy, radiation, or surgery received 
either TPF (docetaxel 75 mg/m2 and cisplatin 100 mg/m2 
Day 1, plus 5-FU 1000 mg/m2 Days 1–4, every 3 weeks 
for 3 cycles) or PF (cisplatin 100 mg/m2 Day 1 plus 5-FU 
1000 mg/m2 Days 1–5, every 3 weeks for 3 cycles) followed 
by CCRT, which was planned to deliver daily radiation Therapeutics and Clinical Risk Management 2008:4(5) 871
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for 5 days per week simultaneously with weekly Cb at 
an area under the curve (AUC) of 1.5 (Calvert formula). 
The primary endpoint was OS, with secondary endpoints 
including PFS and safety.
The results of TAX 324 demonstrated a 14% absolute 
improvement in 3-year survival, with a 30% reduction in 
risk of death for ICT with TPF compared with PF. Median 
OS was significantly longer in the TPF arm compared 
with the PF arm (71 months vs 30 months; HR: 0.70; 95% 
CI: 0.54–0.90; p = 0.006), with survival rates at 1, 2, and 3 
years and pre- and post-CCRT response rates (RRs) also 
higher in the TPF arm (Table 3).
As with TAX 323, the overall incidence of grade 3/4 
hematologic toxicities was predictably higher in the TPF 
arm than in the PF arm, including neutropenia (83% vs 
56%, respectively), febrile neutropenia (12% vs 7%, 
respectively), and neutropenic infection (12% vs 8%, 
respectively). In parallel to the differential AE proﬁ  les 
seen between the 2 arms of TAX 323, PF was associated 
with a higher incidence of grade 3/4 stomatitis, lethargy, 
vomiting, and altered hearing compared with TPF in the 
TAX 324 trial (Table 3).
Other trials of TPF induction + CCRT 
VS CCRT alone
Two phase II/early phase III trials are currently underway, 
both of which have recently provided preliminary data sug-
gesting that ICT with TPF followed by CCRT may be more 
effective than CCRT alone in unresectable LA SCCHN. In 
the ﬁ  rst study, patients in Arm A received 2 cycles of cisplatin 
20 mg/m2 Days 1–4 plus 5-FU 800 mg/m2 over a 96-hour 
continuous infusion at weeks 1 and 4 of RT (66–70 Gy); 
patients in Arm B received ICT with TPF (docetaxel 75 mg/m2 
and cisplatin 80 mg/m2 Day 1, plus 5-FU 800 mg/m2 over a 
96-hour continuous infusion), followed by the same CCRT 
regimen as in Arm A (Ghi et al 2006). Preliminary efﬁ  cacy 
results showed a radiologic CR in 64% (95% CI: 45%–80%) of 
patients in Arm B, compared with 20% (95% CI: 8%–37%) in 
Arm A. During CCRT, grade 3/4 AEs occurring in Arms A and 
B, respectively, were mucositis (42% vs 26%, respectively), 
dysphagia (20% vs 9%), skin reaction (12% vs 8.6%), asthe-
nia (5% vs 3%), grade 3 weight loss (2% vs 3%), and grade 
3 mouth dryness (0% vs 3%). Grade 3/4 granulocytopenia 
occurred in 56% of patients receiving TPF ICT, while febrile 
neutropenia occurred in 7.5% of patients in this group.
Table 2 TAX 323: select efﬁ  cacy and safety results
Results PF TPF
Efﬁ  cacy n =181 n = 177
Median PFS, months 8.2 11.0a
Median OS, months 14.5 18.8b
Response rates, %
  ORR, chemotherapy alone 54 68c
 ORR,  chemotherapy  + radiation 59 72d
  Complete RR, chemotherapy alone 6.6 8.5
  Complete RR, chemotherapy + radiation 19.9 33.3e
Major safety n = 179 n = 173
Grade 3/4 hematologic toxicity, % patients
 Leukopenia 22.9 41.6
 Neutropenia 52.5 76.9
 Thrombocytopenia 17.9 5.2
 Anemia 12.8 9.2
 Febrile  neutropenia 2.8 5.2
Grade 3/4 non-hematologic toxicity, % 
patients
 Alopecia 0 11.6
 Anorexia 3.4 0.6
 Infection 6.1 6.9
 Stomatitis 11.2 4.6
ap = 0.007 vs PF; bp = 0.002 vs PF; cp = 0.006 vs PF; dp = 0.0063 vs PF; ep = 0.004 vs PF.
Abbreviations: ORR, overall response rate; OS, overall survival; PF, cisplatin–5-ﬂ  uorouracil; PFS, progression-free survival; RR, response rate; TPF, docetaxel + cisplatin + 
5-ﬂ  uorouracil.Therapeutics and Clinical Risk Management 2008:4(5) 872
Rapidis et al
In the second study, 295 patients received 3 cycles of ICT 
with either TPF (docetaxel 75 mg/m2 and cisplatin 75 mg/m2 
Day 1, plus 5-FU 750 mg/m2 Days 1–5, every 3 weeks, plus 
granulocyte-colony stimulating factor and antibiotic prophy-
laxis with ciproﬂ  oxacin) or PF (cisplatin 100 mg/m2 Day 1, 
followed by 5-FU 1000 mg/m2 Days 1–5, every 3 weeks) (Hitt 
et al 2006b). Each induction regimen was followed by CCRT, 
delivered as conventional RT (up to 70 Gy) plus concomitant 
cisplatin 100 mg/m2 on Days 1, 22, and 43. Patients in a third 
treatment arm received conventional CCRT alone. In this study, 
ICT followed by CCRT resulted in a higher CR rate compared 
with CCRT alone (70% vs 49%, respectively; p = 0.02), although 
there was no difference between the PF and TPF induction 
groups. Time to progression (TTP) was longest in the TPF group 
(16 months), followed by PF (12 months) and CCRT alone 
(8 months) (log-rank p = 0.02). Mucositis occurred in 60% of 
patients in the PF group, 55% in the TPF group, and 36% in the 
CCRT alone group. Final results, including OS and PFS data, 
are eagerly awaited for both aforementioned trials.
TPF induction therapy plus RT for organ 
preservation: GORTEC 2000–01
TPF induction followed by RT may also be beneﬁ  cial in terms 
of organ preservation, which can be an important factor to 
consider in the treatment of head and neck cancer. The French 
Groupe d’Oncologie Radiotherapie Tete et Cou (GORTEC) 
2000–01 study randomized 220 patients with cancer of the 
hypopharynx or larynx to ICT with TPF or PF, followed by 
RT (Calais et al 2006). TPF followed by RT provided larynx 
preservation in 80% of patients, compared with 57.6% of 
patients receiving upfront PF. Compliance was also greater 
in the TPF arm, which was associated with a higher ORR 
(82.8% vs 60.8%; p = 0.0013) and improved tolerability of 
the entire treatment sequence.
Docetaxel-containing doublets/triplets administered 
as concurrent chemoradiotherapy: TP ± F CCRT trials
As mentioned in previous sections, the aim of CCRT is to 
deliver systemically active chemotherapeutic agents, while 
Table 3 TAX 324: select efﬁ  cacy and safety results
Results PF TPF
Efﬁ  cacy n = 246 n = 255
OS
 Median,  months 30 71a
 2-year,  % 55 67
 3-year,  % 48 62
PFS
 Median,  months 13 36b
 2-year,  % 42 53
 3-year,  % 37 49
Response rate, %
 ORR,  post-chemotherapy 64 72c
 CR,  post-chemotherapy 15 17d
Major safety n = 243 n = 251
Grade 3/4 hematologic toxicity, % patients
 Neutropenia 56 83
 Febrile  neutropenia 7 12
 Neutropenic  infection 8 12
Grade 3/4 non-hematologic toxicity, % patients
 Stomatitis 27 21
 Lethargy 10 5
 Vomiting 10 8
 Diarrhea 37
 Nausea 14 14
ap = 0.006 vs PF; bp = 0.004 vs PF; cp = 0.07 vs PF; dp = 0.66 vs PF.
Abbreviations: CR, complete response; ORR, overall response rate; OS, overall survival; PF, cisplatin–5-ﬂ  uorouracil; PFS, progression-free survival; TPF, docetaxel + cisplatin + 
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capitalizing on their radiosensitizing activity; this treatment 
approach is associated with promising efﬁ  cacy, and has 
become the dominant treatment modality for certain 
SCCHN subtypes (such as nasopharyngeal carcinoma) in 
many tertiary centers (Hoffman et al 2004). Several recent 
studies have shown that docetaxel-cisplatin (TP) CCRT 
combination therapies are reasonably well tolerated and 
moderately effective, with high ORRs (Bouillet et al 2007; 
Kandil et al 2007; Minea et al 2007; Sayed et al 2007; 
Tsao et al 2007).
These early phase trials are encouraging with regard to 
the efﬁ  cacy of the docetaxel−cisplatin combination when it 
is delivered concomitantly with RT. However, docetaxel is 
not approved for CCRT or for palliative use, and phase III 
studies are needed in order to support these data and further 
evaluate late side effects.
Concurrent TPF CCRT vs TPF induction followed 
by radiation therapy
In a trial of 30 patients with LA SCCHN, TPF CCRT was 
more effective than TPF ICT followed by RT, although it was 
associated with more toxicity and required more supportive 
care (Katori et al 2005). Patients in the induction therapy 
group received 2 cycles of docetaxel 60 mg/m2 Day 1, cis-
platin 70 mg/m2 Day 4, and 5-FU 750 mg/m2/day Days 1–5, 
followed by RT (as the sole modality for deﬁ  nitive local/
regional treatment), starting 21 days after completion of che-
motherapy, while patients in the TPF CCRT group received 2 
cycles of docetaxel 50 mg/m2 Day 1, cisplatin 60 mg/m2 Day 
4, and 5-FU 600 mg/m2/day Days 1–5, concomitantly with 
radiation (1.8–2.0 Gy/fraction/day) starting on the ﬁ  rst day of 
chemotherapy. The total radiation dose delivered was 64 to 70 
(mean 66.9) Gy in the TPF induction group and 63.0 to 74.0 
(mean 67.8) Gy in the TPF CCRT group. While the ORR 
and CR rates were similar in both groups (ORR: 100% in 
both groups; CR: 84% for the induction TPF group vs 87% 
for the TPF CCRT group), the 3-year survival rate was 
signiﬁ  cantly higher with concurrent TPF chemoradiotherapy 
compared with induction TPF chemotherapy followed by RT 
alone (83% vs 64%, respectively; p = 0.029). However, the 
AE rate was higher in the TPF CCRT treatment group. Not 
unexpectedly, mucositis and anemia were signiﬁ  cantly more 
prevalent with concurrent TPF compared with induction TPF 
(79% vs 40%, and 16% vs 0%, respectively), as one of the 
consequences of exploiting the radiosensitizing properties of 
chemotherapy within a CCRT regimen is that adjacent normal 
tissue within the ﬁ  eld is also subject to more effective – and 
more toxic – RT.
TPF CCRT: hyperfractionation vs conventional 
fractionation of the RT component
Hyperfractionation of RT within a given CCRT regimen 
may further improve RRs compared with conventional 
fractionation. In a study of 44 patients with previously 
untreated stage III-IV SCCHN, local-regional disease control, 
disease-free survival (DFS), and OS improved with TPF 
given concurrently via hyperfractionated RT compared with 
TPF given concurrently with conventionally fractionated RT 
(Katori et al 2006). All patients received docetaxel 50 mg/m2 
Day 1, cisplatin 60 mg/m2 Day 4 plus 5-FU 600 mg/m2 Days 
1–5, every 4 weeks for 2 cycles, plus either hyperfractionated 
CCRT (1.2 Gy/fraction, twice daily 5 days per week to a total 
of 76.8 Gy/64 fractions) or conventionally fractionated CCRT 
(2 Gy/fraction/day, 5 days per week to a total of 70 Gy/35 
fractions).
In the CCRT arm using hyperfractionated radiation 
delivery (hyperfractionated CCRT), the overall clinical 
response and pCR rates were 100% and 90%, respectively, 
compared with 100% and 81% in the conventional fraction-
ation arm. However, and perhaps unsurprisingly, the incidence 
of mucositis was higher with hyperfractionation (p = 0.048). 
Trends to improvement with TPF given concomitantly with 
hyperfractionated CCRT were observed at 2 years for LRC 
vs conventional fractionation (90% vs 74%; p = 0.085), DFS 
(80% vs 64%; p = 0.091), and OS (90% vs 72%; p = 0.080).
Although the studies reported by Katori and colleagues 
(Katori et al 2005, 2006) are small and the conclusions on 
treatment beneﬁ  t should be made with caution, the results 
are not isolated and provide further supporting evidence that 
TPF hyperfractionated CCRT is more effective than either 
TPF ICT followed by RT or TPF CCRT using conventional 
RT fractionation.
Role of TPF in management of LA disease
Results from several studies presented above, and most 
decidedly the pivotal TAX 323 and TAX 324 clinical trials, 
demonstrate that the addition of docetaxel to the PF regimen 
results in signiﬁ  cantly improved efﬁ  cacy, establishing TPF as 
a highly effective ICT combination regimen for the treatment 
of LA SCCHN. Of note, in the MACH-NC meta-analysis 
(Pignon et al 2000), while the addition of ICT in general (any 
combination regimen) did not offer a statistically signiﬁ  cant 
beneﬁ  t in terms of OS, a post hoc analysis of the ICT trials 
using speciﬁ  cally the PF combination showed a signiﬁ  cant 
absolute beneﬁ  t of 4% in 5-year survival. Taking into con-
sideration the limitations of subgroup post hoc secondary 
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difference due to PF ICT to be signiﬁ  cant. Nevertheless, if 
one integrates this information with the beneﬁ  ts gained from 
the addition of docetaxel to PF ICT, it is logical to assume 
that the OS beneﬁ  t from TPF ICT followed by RT alone 
would be 4% in 5 years. This beneﬁ  t would then approach 
the absolute survival beneﬁ  t associated with platinum-based 
CCRT. Similar arguments have been put forward by Pignon 
and collaborators in their report of an analysis of all the TPF 
phase I and II studies that preceded the pivotal TAX 323 
and TAX 324 trials (Pignon et al 2004). Consequently, TPF 
represents an advance in the systemic aspect of multimodality 
treatment for LA SCCHN, and may provide an important par-
adigm shift in the treatment of this disease. While recognizing 
the proven value of platinum-based CCRT as a curative-intent 
management standard for LA SCCHN (especially in North 
America), we can surmise that TPF ICT has at least the 
potential to become another standard of care in this indication, 
with efﬁ  cacy results possibly comparable to CCRT. Further, 
the TPF ICT regimen is well poised to provide an effective 
backbone for further reﬁ  nement, including modiﬁ  cation of the 
platinum and ﬂ  uoropyrimidine components of ICT, as well 
as the platinum – and/or ﬂ  uoropyrimidine – component of 
CCRT, and the addition of biologically targeted agents.
At this point, the tolerability proﬁ  le of the TPF com-
bination warrants mentioning. Based on the known side 
effect proﬁ  les for each of the drug components of this trip-
let, TPF represents a regimen with a generally predictable 
AE proﬁ  le, which enables effective disease management. 
Nevertheless, strict enforcement of dose reductions, dose 
delays, and other regimen modiﬁ  cations as needed, and 
careful patient selection (especially regarding performance 
status) are required. Additionally, there is a need for careful 
monitoring for neutropenia (a major docetaxel side effect), 
which was observed (any grade) in 12.1% of patients 
receiving TPF in TAX 324 (Posner et al 2007). The prompt 
management of infections as well as their complications is 
also necessary, the rate of neutropenic infection in the TPF 
arm of TAX 324 being 11.7%. Moreover, in the TAX 324 
TPF cohort, the incidence of grade 3 and 4 “venous system 
events,” which include superﬁ  cial and deep venous throm-
bosis, thrombophlebitis, and pulmonary embolism, was low 
(2.4%) (Posner et al 2007). Although venous thromboem-
bolism is not part of the US Food and Drug Administration 
(FDA) “black box” warning statement with the docetaxel 
label (Taxotere label, Sanoﬁ  -Aventis), there are anecdotal 
observations of venous thrombosis occurrences (Feenstra et al 
2000), which may be of considerable risk and inconvenience, 
particularly in SCCHN patients. Both thrombosis and infec-
tion, not only related to docetaxel use, are indeed relevant to 
patients with prolonged need for central intravenous access, 
which typiﬁ  es many patients with LA SCCHN.
In view of the aforementioned efﬁ  cacy and tolerability 
data, TPF has an important role in the re-establishment of 
ICT as an accepted approach in the management of selected 
LA SCCHN patients. Of note, TPF ICT followed by carbo-
platin-CCRT is also approved by both the US Federal Drug 
Administration (US FDA 2007) and the European Medicines 
Agency (EMEA) (EMEA 2007) for the treatment of LA 
SCCHN. Several pivotal trials are currently investigating 
this potential (Table 4), including DeCIDE and PARA-
DIGM, two ongoing, international, multicenter, randomized, 
pivotal phase III studies comparing upfront TPF induction 
therapy followed by CCRT vs CCRT alone. Notably, the 
DeCIDE trial will evaluate the potential of TPF followed 
by an intensive CCRT regimen, in contrast to most studies 
that have to date used relatively “milder” CCRT. Moreover, 
the importance of gauging the effects of adding upfront TPF 
on organ preservation, a highly relevant endpoint in LA 
SCCHN, is reﬂ  ected in another large study, the TREMPLIN 
trial, which is investigating larynx preservation in approxi-
mately 150 patients in France (Table 4). The role of ICT 
prior to surgery, especially in patients with large primary 
lesions, remains to be established and should be examined 
in phase II studies while awaiting results from the above 
large phase III trials. Such future phase II trials, as well as an 
analysis of the patterns of failure and use of surgery (either 
intercalated between ICT and RT or CCRT, or as salvage 
following the completion of the delivery of the entire treat-
ment program) by secondary data mining from the TAX 323 
and TAX 324 trials will also offer considerable insight to the 
degree and timing of TPF effects on local/regional disease 
control. This is much needed information, as delineating 
these effects could ultimately lead to modiﬁ  cation of the 
CCRT component that would follow ICT, or even introduce 
the possibility of surgical deﬁ  nitive therapy post-ICT (the 
latter in highly selected patients). This is especially impor-
tant in the era of targeted therapy agents and less extensive 
surgical approaches (eg, supracricoid subtotal laryngectomy 
and its variants), which will be predictably integrated in the 
sequential treatment program (ICT followed by CCRT ± 
surgery) in the near future.
Docetaxel in metastatic
or recurrent disease
Despite optimal therapy, local or regional recurrence 
occurs in more than 50% of patients with SCCHN, with Therapeutics and Clinical Risk Management 2008:4(5) 875
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approximately 30% of such patients developing distant 
metastases (Gedlicka et al 2002). Although initial presen-
tation with metastatic (M1) disease is relatively rare (Hitt 
et al 2006a), chemotherapy in the context of recurrent or 
metastatic disease has, until recently, been largely palliative 
in nature. The promising activity of docetaxel given alone 
or in combination with other agents, however, has been 
investigated in several recent studies, and may provide the 
basis for improved outcomes in patients who currently face 
a very poor prognosis.
Docetaxel alone or in combinations
for metastatic or recurrent SCCHN
Docetaxel monotherapy
Docetaxel monotherapy has been investigated in 3 recent 
trials. In the ﬁ  rst, docetaxel (40 mg/m2/week until disease 
progression or limiting toxicity) monotherapy was com-
pared with methotrexate (40 mg/m2/week until disease 
progression or limiting toxicity) monotherapy (Guardiola 
et al 2004), and was associated with a signiﬁ  cantly higher 
objective RR (27.0% [95% CI: 21.7%–32.3%] vs 15.0% 
[95% CI: 11.2%–18.8%], respectively) in 57 patients with 
recurrent (n = 28) or metastatic (n = 29) SCCHN. The median 
response duration was longer with docetaxel (8.6 [range 
1.7–17.6] months vs 6.2 [range 2.8–10.6] months), although 
the time to progression (TTP) and OS endpoints were simi-
lar between the 2 groups (1.97 [range 1–19] and 3.7 [range 
0.13–10.0] months, respectively, for docetaxel monotherapy, 
vs 1.5 [range 1.0–12.0] and 3.9 [range 0.2–11.8] months, 
respectively, for methotrexate monotherapy). In this trial, 
side effects, particularly hematologic events, were more 
common in the docetaxel arm.
In a non-comparative phase II trial of weekly docetaxel 
monotherapy (30 mg/m2 every 4 out of 5 weeks, to a 
maximum of 6 cycles), the ORR was 42% among 38 patients 
with M/R SCCHN (Hitt et al 2006a). The median response 
duration for patients with PR was 8.39 (95% CI: 8.28–11.5) 
months, with a median TTP of 10 months. Median OS was 
11.3 months, with a 1-year survival rate of 39%. It is notable 
that no grade 3 or 4 AEs were reported.
The third monotherapy trial investigated weekly 
docetaxel 35 mg/m2 for 3 out of every 4 weeks (Koussis 
et al 2007). A total of 24 patients with recurrent or metastatic 
SCCHN were enrolled in this study, all of whom had previ-
ously received platinum-based therapy. There were 6 PRs 
(25%) with a mean duration of 3.4 months. Stable disease 
(SD) was observed in 6 patients (25%) and progressive dis-
ease in 12 patients (50%). Toxicity was mild and consisted 
of grade 4 mucositis in 3 patients (12.5%) and grade 3/4 
hematologic toxicity in 4 patients (17%).
Docetaxel doublet chemotherapy
As the TPF triplet has shown signiﬁ  cant activity in the LA 
disease setting, docetaxel has been investigated in the recur-
rent or metastatic disease setting as a doublet combination 
with one of the other two components of TPF. The most 
commonly investigated combination regimens are based on 
docetaxel plus cisplatin; this combination has achieved RRs 
of 42% to 80% and median OS durations of 10 to 13 months 
(Table 5) (Gedlicka et al 2002; Yabuuchi et al 2003; Hehr 
et al 2005; Baghi et al 2006; Guntinas-Lichius et al 2006; 
Peyrade et al 2006).
In a phase III study, 568 patients with locally recurrent 
or metastatic SCCHN received either docetaxel 75 mg/m2 
plus cisplatin 75 mg/m2 on Day 1, every 3 weeks (TP), 
or cisplatin 100 mg/m2 on Day 1 followed by 5-FU 
1000 mg/m2/day for 5 days, every 3 weeks (PF). For the 
primary endpoint of median TTP, the difference between 
groups was not statistically signiﬁ  cant (p = 0.25); median 
TTP was 2.8 months in the TP group (95% CI: 2.6–3.7 
months) vs 3.2 months in the PF group (95% CI: 2.9–3.9). 
The incidences of grade 3/4 leukopenia and grade 3/4 
neutropenia were higher in the TC group (59.9% and 70.1%, 
respectively) than in the CF group (38.1% and 51.7%, 
respectively). Conversely, thrombocytopenia was more 
common in the CF group than in the TC group (all grades, 
42.6% vs 16.6%; grade 3/4, 15.1% vs 4.8%, respectively) 
(ClinicalStudyResults.org 2008).
Docetaxel has also been investigated in combination 
with other cytotoxic agents. Docetaxel plus the vinca 
alkaloid vinorelbine was active in 29 heavily pretreated 
patients with recurrent SCCHN (Airoldi et al 2003). In this 
study, patients (21 with local-regional recurrence, 8 with 
metastatic disease) had been previously treated with CCRT 
(n = 14), surgery plus adjuvant RT (n = 13), surgery plus 
CCRT (n = 1), or RT alone (n = 1); 9 patients had received 1 
courses of palliative chemotherapy. Docetaxel (80 mg/m2) 
and vinorelbine (20 mg/m2) were administered on Day 1 
every 3 weeks for a maximum of 6 cycles.
The ORR was 49%, including 3 CRs (10%; median 
duration 20 months) and 11 PRs (38%; median duration 
5.5 months). The most frequent serious AE was neutro-
penia (grade 3, 21%; grade 4, 79%). The ﬁ  rst 12 patients 
experienced grade 3 (14%) and grade 4 (7%) infection, 
but with the addition of ciprofloxacin prophylaxis, the 
following 17 patients did not experience this type of event.Therapeutics and Clinical Risk Management 2008:4(5) 876
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Table 4 Ongoing pivotal trials of docetaxel-based chemotherapy (Clinicaltrials.gov 2008)
Name Sponsor/ collaborator Primary investigator Primary site Planned 
patient no
Cooperative group or independent investigator-initiated clinical trials
→ Pivotal trials
1    A phase III trial of docetaxel-based chemoradio-
therapy plus or minus induction chemotherapy to 
decrease events in head and neck cancer in N2/N3 
stage patients (the DeCIDE trial)
UofC IRB #: 13362B
University of Chicago Ezra Cohen, Everett 
Vokes (co-PIs, Univer-
sity of Chicago, Chicago, 
IL, USA)
International 
multicenter
400
2     A phase III study of sequential therapy with TPF/
chemoradiation vs cisplatin-based chemoradio-
therapy with accelerated concomitant boost RT 
for LA squamous cell cancer of the head and neck 
(the PARADIGM trial)
DFCI trial #: 04–006
Dana-Farber Cancer Institute 
(DCFI)
Marshall Posner, Robert 
Haddad (co-PIs, DCFI, 
Boston, MA, USA)
International 
multicenter
330
→ Other trials (combining docetaxel with biologics)
3     Larynx preservation with induction chemo-
therapy (cisplatin, 5-FU, docetaxel) followed by RT 
combined with either cisplatin or cetuximab in 
laryngopharyngeal squamous cell carcinoma – a 
randomized phase II study (the “TREMPLIN” study)
Groupe Oncologie Radiother-
apie Tete et Cou (GORTEC)
Groupe d’Etude des Tumeurs 
de la Tete et du Cou 
(GETTEC)
Jean-Louis Lefebvre (PI, 
Centre Oscar Lambret, 
Lille, France)
France, 
multicenter
156
4     Phase II trial of combination weekly bortezomib 
(Velcade®) and docetaxel (Taxotere®) in patients 
with recurrent and/or metastatic head and neck 
squamous cell carcinoma
(VICC study #: HN0501)
Vanderbilt-Ingram Cancer 
Center (VICC) NCI
Christine Chung (Study 
Chair,   VICC, Nashville, 
TN, USA)
US, multi-
center
50
5     A phase II study of bevacizumab (Avastin®) in 
combination with docetaxel and radiation on LA 
squamous cell cancer of the head and neck
(CASE CCC Study #: 6304)
Case-Western 
Reserve – Ireland Compre-
hensive Cancer Center 
(CWRU ICC)
NCI
Panos Savvides (Study 
Chair, Case Compre-
hensive Cancer Center, 
Cleveland, OH, USA)
Case 
Comprehensive 
Cancer Center, 
Cleveland, OH, 
USA)
30
6     Phase III trial of TPF induction therapy + 
cisplatin/5-ﬂ  uorouracil with concomitant RT with 
or without cetuximab (Erbitux®) in patients with 
squamous cell carcinoma of the head and neck
(the AVAPO trial)
SS Giovanni and Paolo 
Hospital (Associazione 
Volontari Assistenza Pazienti 
Oncologia: AVAPO)
Adriano Paccagnella, PI, 
SS Giovanni and Paolo 
Hospital, Venice, Italy
Italy, 
Multicenter
350
7     EORTC 24061: Randomized phase II feasibility 
study of cetuximab (Erbitux®) combined with 
4 cycles of TPF followed by platinum-based 
chemoradiation strategies
European Organisation for 
Research and Treatment of 
Cancer (EORTC) Head and 
Neck Group
Jan Baptiste Vermorken 
(Study coordinator, 
Universitair Ziekenhuis 
Antwerpen, Edegem, 
Belgium)
EU, 
multicentre
55
8     Organ preservation trial for advanced primary 
untreated squamous cell carcinoma of the phar-
ynx and larynx (Stage III/IV)
Dept of ORL and Head and 
Neck Surgery, University 
Clinic – Frankfurt, Frankfurt, 
Germany
Rainald Knecht (Chief 
Investigator, University 
Clinic – Frankfurt, 
Frankfurt, Germany)
Volker Budach (Chief 
Co-Investigator, Klinik 
und Poliklinik fuer 
Strahlentherapie, 
University Clinic – Berlin, 
Berlin, Germany)
Germany, 
multicenter
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Design/disease stage Treatmentsa Primary objective Year started
Randomized, open label, LA 
SCCHN (only N2/N3)
2 cycles of TPF ICT vs no induction CT followed by 
RT plus docetaxel/5-FU and oral hydroxyurea
OS 2004
Randomized, open label
LA SCCHN
Arm A: 3 cycles of TPF ICT followed by CCRT; 
splitting of the arm:
Arm A1 (poor response during induction): 
docetaxel weekly for 4 weeks + RT with accelerated 
concomitant boost
Arm A2 (good response during induction): 
carboplatin + RT
Arm B: no induction CT; cisplatin + RT
OS 2004
Randomized, open label, 
parallel group LA SCC
larynx 
3 cycles of TPF followed by RT plus either 3-wkly 
cisplatin x 3 or cetuximab (loading dose then wkly) 
for 8 cycles (only in patients with 50% response 
to TPF)
Laryngeal preservation 
rate
2005
Open label
Recurrent/metastatic 
SCCHN
IV docetaxel plus IV bortezomib on Days 1 and 8, 
every 4 wks
ORR 2005
Open label
LA SCCHN
RT once daily, 5 days per wk for 8 wks plus IV 
docetaxel once per wk for 8 wks plus IV bevacizumab 
every 2 wks for up to 1 year
TTP 2005
Randomized, parallel group
LA SCCHN
Arm A: induction chemotherapy (TPF every 3 wks for
3 cycles) then cisplatin + 5-ﬂ  uororacil + RT ± cetuximab
Arm B: cisplatin + 5-ﬂ  uororacil + RT ± cetuximab
(no induction CT)
OS 2007
Randomized, parallel group
LA SCCHN
Arm A: induction with TPF (2 or 4 cycles depending on 
progression) followed by CCRT with wkly cisplatin
Arm B: induction with TPF (2 or 4 cycles depending on 
progression) followed by CCRT with wkly carboplatin
Both arms receive weekly cetuximab throughout
Feasibility of delivery of 
the regimens based on 
80% of the per-protocol 
dose intensity of RT, 
platinum and cetuximab 
during the CCRT phase
Projected: Q2 
2008
Open label, randomized, 
phase III
LA SCCHN
Group 1: TPF (every 3 wks for 3 cycles) followed by 
accelerated RT with concomitant boost + cetuximab
Group 2: no induction CT; accelerated RT with 
concomitant boost + cetuximab
OS Projected: Q2 
2008
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Table 4 (Contiuned)
Name Sponsor/ collaborator Primary investigator Primary site Planned 
patient no
Pharma-sponsored clinical trials (combining docetaxel with biologics)
9     Randomized phase II study of docetaxel in 
combination with vandetanib (Zactima®, ZD6474) 
in patients with LA squamous cell carcinoma of 
the head and neck
DFCI
Brigham and Women’s 
Hospital (BWH)
Beth Israel Deaconess 
Medical Center (BIDMC)
Massachusetts General 
Hospital (MGH)
AstraZeneca
Robert Haddad 
(PI, DFCI, Harvard 
Medical School, Boston, 
Massachusetts, USA)
US, 
multicenter
72
10     Phase II trial of docetaxel, cetuximab (C225; 
Erbitux®), and cisplatin followed by radiation, 
cetuximab, and cisplatin in LA head and neck 
cancer
University of Pittsburgh 
Bristol-Myers Squibb (BMS)
Athanassios (Ethan) 
Argiris (PI, University of 
Pittsburgh, Pittsburgh, 
PA, USA)
University of 
Pittsburgh, 
Pittsburgh, PA, 
USA
40
11     A randomized, open-label, controlled, phase II trial 
of combination chemotherapy with or without 
panitumumab (Vectibix®) as ﬁ  rst-line treatment 
of subjects with metastatic or recurrent head 
and neck cancer, and cross-over second-line pani-
tumumab monotherapy of patients who fail the 
combination chemotherapy (the PARTNER trial: 
Panitumumab Added to Regimen for Treatment of 
head and Neck cancer – Evaluation of Response)
Amgen Company-coordinated 
trial
Amgen 
Research Site, 
Paducah, KY, 
USA
150
12     Phase I evaluation of erlotinib (Tarceva®) and 
docetaxel with concomitant boost radiation for 
locoregionally advanced squamous cell carci-
noma of the head and neck
University of Texas – M.D. 
Anderson Cancer Center
Genentech
(Also supported – but not 
sponsored – by sanoﬁ  -aventis)
Bonnie S. Glisson (PI, 
M.D. Anderson Cancer 
Center, Houston, TX, 
USA)
M.D.   Ander-
son Cancer 
Center, 
Houston, TX, 
USA
24
13     Phase I sequential therapy: Panitumumab 
(Vectibix®) (P)-TPF plus P-CT chemoradio-
therapy
DFCI Trial #: 05–401
DFCI
Amgen
Marshall Posner, Robert 
Haddad (co-PIs, DFCI, 
Boston, MA, USA)
US, single 
center
24
14     GSTTC: one-step four-arm randomized trial of 
TPF induction chemotherapy followed by PF + 
cetuximab (Erbitux®) in patients with squamous 
cell carcinoma of the head and neck
Gruppo di Studio sui Tumori 
della Testa e Collo (GSTTC)
Merck KGaA
Adriano Paccagnella, PI, 
Venice, Italy
Italy, multi-
center
300
15     DFCI: TPF plus cetuximab (Erbitux®) (TPF-3) 
phase I trial of sequential chemotherapy and 
cetuximab
DFCI Trial #: 06–128
DFCI
BMS
Robert Haddad (PI, 
DFCI, Harvard Medical 
School, Boston, MA, 
USA)
US, multi-
center
30–40
Docetaxel in combination with the topoisomerase I 
inhibitor irinotecan (Tax-Iri) has demonstrated activity in 
M/R SCCHN, with acceptable and predominantly gastroin-
testinal side effects (Argiris et al 2005). This combination 
is of interest as the 2 drugs have partially non-overlapping 
side effect proﬁ  les, and there is preclinical evidence of 
synergistic activity, with phase I studies demonstrating that 
both drugs can be given safely in a weekly schedule. In 
this study, patients were divided into 2 cohorts: those who 
were chemotherapy-naïve (n = 17) and those who had been 
previously treated with 1 chemotherapy regimen (n = 37). 
The study regimen consisted of docetaxel 35 mg/m2 plus 
irinotecan 60 mg/m2 on Days 1 and 8, every 3 weeks, until 
disease progression or limiting toxicity.
With response data available for 47 patients, there were 
4 objective PRs in 17 chemotherapy-naïve patients (24%), 
and 1 PR in 30 pretreated patients (3%). Median PFS and OS 
durations were longer among chemotherapy-naïve patients Therapeutics and Clinical Risk Management 2008:4(5) 879
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Design/disease stage Treatmentsa Primary objective Year started
Phase II, randomized, open 
label, parallel group
LA SCCHN
Docetaxel once every 3 wks plus vandetanib
once daily
Response rate March 2007
Phase II, open label, non-
randomized, parallel group
LA SCCHN
Docetaxel plus cetuximab plus cisplatin followed
by RT + cetuximab + cisplatin
Objective response rate 2005
Phase II, randomized, open 
label, parallel group
Recurrent/metastatic 
SCCHN
Docetaxel plus cisplatin ± panitumumab PFS 2007
Phase I, non-randomized, 
open label
Docetaxel 15 or 20 mg/m2 on Days 1, 8, 15, and 22 
plus oral erlotinib 100, 125, or 150 mg on all other 
days the patient is not receiving docetaxel + RT 
(includes concomitant boost)
Maximum tolerated dose 
of docetaxel + erlotinib 
during concomitant 
boost radiation
2005
Phase I, non-randomized, 
open label
Docetaxel + cisplatin + 5-FU + panitumumab, every
3 wks for 3 cycles, followed by panitumumab + 
carboplatin + paclitaxel with daily RT
Maximum tolerated 
dose of docetaxel and 
panitumumab in the 
delivered schema
2007
Randomized, parallel group Arm A: TPF induction chemotherapy then either PF or 
cetuximab
Arm B: no induction therapy, followed by either PF or 
cetuximab
ORR; TTP Projected: 
2008
Phase I, non-randomized, 
open label
TPF + cetuximab followed by platinum-based chemo-
radiotherapy
Maximum tolerated 
dose of docetaxel and 
cetuximab in the deliv-
ered schema
2007
Abbreviations: 5-FU, 5-ﬂ  uororoucil; IV, intravenous; LA, locally advanced; ORR, overall response rate; PFS, progression-free survival; PI, principal investigator; RT, radiotherapy; 
SCCHN, squamous cell carcinoma of the head and neck; TPF, docetaxel + cisplatin + 5-ﬂ  uorouracil; TTP, time to progression.
(3.2 and 9.8 months, respectively) compared with pretreated 
patients (1.8 and 5.2 months, respectively). The main AEs 
(51 evaluable patients) included neutropenia (grade 3, 8%; 
grade 4, 10%), fatigue (grade 3, 16%), anorexia (grade 3, 8%; 
grade 4, 4%), diarrhea (grade 3, 24%; grade 4, 2%), stomatitis 
(grade 3, 2%), vomiting (grade 3, 4%; grade 4, 2%), febrile 
neutropenia (4%), neutropenic infection (grade 3, 2%; 
grade 4, 4%), dyspnea (grade 3, 2%; grade 4, 2%), and 
creatinine abnormality (grade 3, 2%; grade 4, 4%).
Docetaxel has also been combined with 5-FU (TF) 
for the treatment of locally recurrent and/or metastatic 
SCCHN (Genet et al 2004). Patients in this study were 
divided into pretreated (n = 20) and treatment-naïve 
(n = 43) groups, and received docetaxel 75 mg/m2 Day 1 
plus 5-FU 1000 mg/m2 Days 1–5, every 3 weeks. A total 
of 59 patients (94%) had received prior RT. The ORR 
was 20.6%: 25.0% for pretreated vs 18.6% for treatment-
naïve patients. Overall, the major grade 3/4 AEs included Therapeutics and Clinical Risk Management 2008:4(5) 880
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neutropenia (66.6%), febrile neutropenia (31.7%), and 
mucositis (31.7%). After the first 20 patients were 
enrolled, the dose of 5-FU was reduced to 750 mg/m2 
due to toxicity; thereafter, the rate of febrile neutropenia 
fell from 40.0% to 27.9% and that of mucositis fell from 
55.0% to 20.9% (Genet et al 2004).
Docetaxel triplet therapy other than TPF
Triplet therapy using variations on the “standard” TPF 
regimen have also been investigated in several recent trials. 
The combination of docetaxel 50 to 60 mg/m2 and cisplatin 
70 mg/m2 Day 1, plus the oral ﬂ  uoropyrimidine S-1 40 to 
80 mg/m2/day Days 1–14, every 4 weeks (the TPS regimen), 
showed promising antitumor activity in a phase I dose-
escalation study (Tahara et al 2007). A median of 3 cycles 
(range 1–6) of treatment was administered to 22 patients 
with LA or recurrent/metastatic SCCHN; CR was observed 
in 3 patients (1 with locally recurrent disease, 2 with meta-
static disease) and PR in 11 patients (7 with locally recurrent 
disease, 4 with metastatic disease). The ORR was 64%.
Of note, the combination of docetaxel (80 mg/m2 Day 15), 
cisplatin (80 mg/m2 Day 1) and the ﬂ  uoropyrimidine gem-
citabine (1100 mg/m2 Days 1 and 15) (TPG) every 4 weeks 
showed modest activity in 21 patients with relapsed or 
metastatic SCCHN (Kouroussis et al 2005), with an ORR 
of 33% (95% CI: 22.4–55.1). The median duration of 
response was 8.9 months, with a median TTP of 6 months 
and an estimated median OS of 8.1 months. Toxicity 
was manageable, and included febrile neutropenia (4%), 
grade 3/4 neutropenia (41%), grade 3 anemia, mucositis, 
Table 5 Docetaxel–cisplatin as a “core” combination for the treatment of metastatic or recurrent squamous cell carcinoma of the 
head and neck
Reference Regimen Patients, n Complete RR, % ORR, % OS, % Median OS, 
months
1-year 2-year
Gedlicka et al 
(2002)
Docetaxel 75 mg/m2 D1 38 17.5 52.5 50 9 11 (range 1–30)
Cisplatin 75 mg/m2 D1
q3w to 6 cycles
Yabuuchi et al 
(2003)
Docetaxel 60 mg/m2 17 – 71 – – –
Cisplatin 70 mg/m2
Hehr et al (2005) Docetaxel 50 mg/m2 D1 39 – 80 – 20 10
Cisplatin 15 mg/m2 D2-5
q3w for 3 cycles + RT 
2.0 Gy once daily D8–12, 
15–19, 29–33, 36-40
Guntinas-Lichius 
et al (2006)
Docetaxel 35 mg/m2 21 0 42 45 – 10.7
Cisplatin 25 mg/m2 (95% CI: 
6.4–15.0)
D1, 8, 15, q4w
Baghi et al (2006) Docetaxel 75 mg/m2 D1 24 25 42 – – 13 (range 6–48)
Cisplatin 100 mg/m2 D1
5-ﬂ  uorouracil 1000 
mg/m2 D1–4
q3w to 3 cycles
Peyrade et al 
(2006)
Docetaxel 75 mg/m2 D1 40 15 63 – – 13
Cisplatin 75 mg/m2 D1
5-ﬂ  uorouracil 750 mg/m2 
D2–5 q3w
Abbreviations: CI, conﬁ  dence interval; ORR, overall response rate; OS, overall survival; q3w, every 3 weeks ; q4w, every 4 weeks ; RR, response rate; RT, radiotherapy.Therapeutics and Clinical Risk Management 2008:4(5) 881
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asthenia, and vomiting (4% each). Out of 107 cycles given 
cumulatively to the entire cohort during this study, a total of 
19 cycles (18%) were delayed, 16 cycles (15%) were asso-
ciated with dose reductions, and 60 cycles (56%) required 
granulocyte colony-stimulating factor (G-CSF) support. 
A phase II study of doublet therapy using docetaxel 75 mg/m2 
Day 8 plus gemcitabine 1000 mg/m2 Days 1 and 8 (TG or 
GemDoc) every 3 weeks for 6 cycles in patients with recur-
rent and/or metastatic SCCHN, also showed a high incidence 
of grade 3/4 neutropenia (18/40 patients [45%]) (Labourey 
et al 2007).
In view of the more favorable safety proﬁ  le of Cb com-
pared with cisplatin, a docetaxel and Cb combination has 
also been investigated. A total of 96 patients with metastatic 
or recurrent SCCHN participated in this study, and the TCb 
combination was associated with a longer median survival 
duration compared with Pacli-Cb doublet (37 months vs 
10.9 months, respectively) (Bickmann et al 2006). Patients 
enrolled in this trial received either weekly docetaxel 
35 mg/m2 plus Cb AUC 2.0 or paclitaxel 100 mg/m2 plus 
Cb AUC 2.0, for a maximum of 6 cycles. CR was seen 
in 25.0% of patients receiving docetaxel, compared with 
9.6% receiving paclitaxel, while PR was seen in 34.1% of 
patients receiving docetaxel vs 38.5% receiving paclitaxel. 
These data corresponded to an ORR of 59.1% for TCb and 
48.1% for Pacli-Cb. Leukopenia was the most frequent 
toxicity, with grade 1–3 leukopenia occurring in 12.0%, 
27.0%, and 15.0% of paclitaxel recipients, respectively, 
and 25.0%, 23.0%, and 16.0% of docetaxel recipients, 
respectively.
Another triple-therapy combination phase II study 
investigated docetaxel, Cb, and the oral ﬂ  uoropyrimidine 
capecitabine (Xeloda®) (TCb-X) in 21 patients with recurrent 
(n = 15) or metastatic (n = 6) SCCHN (Kattan et al 2005). 
There was 1 CR and 8 PRs, for an ORR of 43%, which was 
comparable with that reported in the literature. The median 
TTP was 4.2 months. It is notable that this regimen was very 
well tolerated, with grade 3/4 anemia and thrombocytopenia 
reported in only 2 patients each (10% of the cohort).
Role of docetaxel in systemic 
chemotherapy in the recurrent/
metastatic disease setting
Summarizing the data presented in the sections above, 
docetaxel-based chemotherapy, whether as single-agent, or 
more importantly as part of doublet- or triplet-chemotherapy 
regimens, shows considerable activity in the recurrent/
metastatic SCCHN setting. Nevertheless, this disease has 
been considered an extremely difﬁ  cult one in which to 
provide truly effective treatment, a fact reﬂ  ected in poor 
rates of long-term survival. Docetaxel-based regimens are 
associated with promising OS and PFS, indicating that further 
investigation to improve outcomes with docetaxel-containing 
templates is warranted.
Future directions
It is likely that the future of docetaxel in the treatment of 
SCCHN lies with TPF, a combination that can be used as the 
platform for curative-intent ICT in LA disease. Evolution of 
this triple-drug regimen toward one that includes platinum 
agents and oral ﬂ  uoropyrimidines other than cisplatin and 
5-FU, as well as molecularly targeted therapies, is the subject 
of recent investigation. Biologic agents as “add-ons” to TPF 
are of particular interest; ongoing trials focusing on these are 
summarized in Table 4.
The epidermal growth factor receptor (EGFR) in 
particular, plays an important role in many epithelial cancer 
types, including that of the head and neck. Overexpression 
of this receptor is associated with increased tumor growth, 
metastasis, resistance to chemotherapeutic agents, and poor 
prognosis (Jones et al 2006). Molecules targeting the EGFR, 
such as erlotinib, geﬁ  tinib, and cetuximab, form an important 
component of novel treatment approaches in combination 
with docetaxel for the treatment of SCCHN. In this section, 
a brief overview of the potential to combine these novel 
targeted agents with TPF is discussed.
Erlotinib
Several recent phase I and II studies have investigated the 
combination of docetaxel and the EGFR tyrosine kinase 
inhibitor (TKI) erlotinib. The feasibility of combining weekly 
docetaxel (15–20 mg/m2) with daily erlotinib (50–100 mg), 
and concomitantly delivered RT (1.8 Gy/day to 70.2 Gy) 
was demonstrated in a phase I study in patients with LA 
stage III-IVb SCCHN (Savvides et al 2006). Following 
docetaxel–erlotinib CCRT, best response observed was CR 
in 15/18 patients (83%); 2 patients were not evaluable and 
1 died during the study.
The activity of docetaxel, erlotinib, and cisplatin combi-
nation chemotherapy was also encouraging in a phase II trial 
of 37 patients with metastatic or recurrent SCCHN (Kim et al 
2006). Patients received docetaxel 75 mg/m2 and cisplatin 
75 mg/m2, every 3 weeks, with daily erlotinib 150 mg; G-CSF 
support was also administered. Treatment was associated 
with CR in 3 patients, PR in 18 patients, and SD in 8 patients, Therapeutics and Clinical Risk Management 2008:4(5) 882
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corresponding to an ORR of 66% and an impressive disease 
control rate of 91%. Treatment was well tolerated, with the 
main AEs being grade 3/4 neutropenia (14%, including 5% 
with febrile neutropenia), grade 4 diarrhea (3%), and grade 
3 rash (5% patients).
Geﬁ  tinib
Another EGFR TKI, geﬁ  tinib, has been investigated in 
combination with docetaxel-based regimens for the treatment 
of SCCHN. The addition of geﬁ  tinib to the well-established 
TP combination was investigated in a phase II trial 
in 23 patients with recurrent /metastatic SCCHN (Belon et al 
2005). Among 16 patients eligible for efﬁ  cacy analysis, after 
a median of 4 cycles of TP (75 mg/m2 each, every 3 weeks) 
and 71 days (range 7–244) of geﬁ  tinib therapy (250 mg/day), 
there were 6 CRs (37.5%) and 4 PRs (25.0%), corresponding 
to an ORR of 62.5% (95% CI: 35.4–84.8). The disease control 
rate was 75.0% (95% CI: 47.6–92.7). In this trial, the median 
PFS of 5.1 months (95% CI: 2.0–7.1) was of interest, given 
that the expected OS of patients with recurrent and/or meta-
static SCCHN is only usually 6 months (Belon et al 2005). 
All 17 patients were eligible for safety analysis, with grade 
3/4 AEs including neutropenia (41.2% of patients, including 
23.5% with febrile neutropenia), anemia (17.7%), asthenia 
(11.8%), and diarrhea, vomiting, anorexia, and leukopenia 
(5.9% each).
Cetuximab (C225)
Cetuximab (Erbitux®), a chimeric IgG1 monoclonal antibody 
directed against the extracellular domain of the EGFR, has 
been investigated in combination with RT and as part of a 
docetaxel-based induction regimen for the management of 
LA SCCHN.
In a phase III study that compared RT alone with 
cetuximab plus RT, the combination of cetuximab plus 
RT improved LRC and increased the OS of patients with 
LA SCCHN vs RT alone (49 months vs 29.3 months, 
respectively); however, severe toxicity in the form of 
acneiform rashes and infusion reactions – occasionally life-
threatening – occurred in the group receiving the cetuximab/
RT combination, but not in the group receiving RT alone 
(Bonner et al 2006).
In a phase II study, 21 previously untreated patients 
with stage III/IV (M1) or selected stage II (base of tongue, 
hypopharynx or nasopharynx) SCCHN received docetaxel 
75 mg/m2 and cisplatin 75 mg/m2 Day 1, plus cetuximab 
400 mg/m2 loading dose Day 1 then 250 mg/m2 on Days 1, 
8, and 15, every 3 weeks for 3 cycles (the TP-E regimen) 
(Argiris et al 2007). Patients went on to receive concomitant 
bio-chemoradiotherapy as RT (2 Gy/day to 70 Gy) with 
concurrent weekly cisplatin (30 mg/m2) and cetuximab 
(250 mg/m2), followed by cetuximab maintenance therapy 
for 6 months. The ORR among 16 evaluable patients was 
94.0% (CR: 12.5%; PR: 75.0%; SD: 6.25%). Twenty patients 
were eligible for the safety analysis; serious AEs included 
neutropenia (grade 3, 20%; grade 4, 35%), anemia (grade 3, 
5%), thrombocytopenia (grade 3, 5%), hypomagnesemia 
(grade 3, 10%; grade 4, 5%), rash, fatigue, and diarrhea (5%, 
grade 3 for each). One patient experienced grade 3 infusion 
reaction during the ﬁ  rst administration of cetuximab and was 
withdrawn from the study.
Recently, a retrospective efﬁ  cacy analysis showed that the 
combination of TP–5-FU induction therapy with cetuximab 
is feasible, resulting in a primary site ORR of 71% (CR: 
14%; PR: 57%) in 21 consecutively treated patients with 
LA SCCHN (Kuperman et al 2007). The ORR at regional 
nodes was 83% (CR: 39%; PR: 44%). Neutropenic infection 
and grade 3/4 infusion reactions were observed in 19% of 
patients each, and grade 3/4 sepsis in 5%.
It should be noted that the combination of paclitaxel 
with cetuximab has been shown to result in high levels of 
skin toxicity (grade 3 or 4 in 24% of patients) (Hitt et al 
2007). As there are currently only a few preliminary stud-
ies docetaxel and cetuximab, it is not possible to predict at 
this time what levels of skin toxicities may occur with this 
combination.
RNA-interfering molecules
Novel approaches to target the EGFR in cancer include the 
diminution of EGFR expression using interfering molecules 
and antibodies; in fact, several recent preclinical studies have 
investigated the potential of EGFR in pre-transcriptional 
inhibition of the EGFR gene to enhance the activity of con-
ventional chemotherapeutic agents (Niwa et al 2003; Nozawa 
et al 2006). The addition of EGFR small interfering RNA 
(siRNA) to cisplatin, 5-FU, and docetaxel enhanced chemo-
sensitivity (Nozawa et al 2006). The siRNA acts to efﬁ  ciently 
downregulate EGFR expression, inhibiting cell growth and 
enhancing chemosensitivity to TP therapy, resulting in a sig-
niﬁ  cant increase in apoptosis. In an SCCHN xenograft model, 
EGFR siRNA delivered by atelocollagen enhanced the anti-
tumor activity of cisplatin, suggesting that this combination 
may improve chemotherapeutic efﬁ  cacy in the clinic. Similar 
enhancement of docetaxel activity was observed in SCCHN 
cell lines and xenografts treated with an EGFR antisense oli-
gonucleotide targeting region 760–779 of the EGFR mRNA Therapeutics and Clinical Risk Management 2008:4(5) 883
Docetaxel in head and neck cancer
(Niwa et al 2003). Increased cytotoxicity was observed 
with TPF compared with EGFR sense oligonucleotide plus 
docetaxel (or docetaxel alone). Furthermore, addition of the 
anti-EGFR antibody to TPF signiﬁ  cantly reduced the mouse 
xenograft tumor volumes. Of note, the TPF triplet plus an 
anti-EGFR antibody achieved complete remissions lasting 
up to 6 weeks in another preclinical study in mouse SCCHN 
xenografts (Knecht et al 2003).
In view of the promising activity of novel biologic 
and targeted agents when used in combination with 
docetaxel-based chemotherapy, several trials investigating 
the incorporation of targeted therapies, including erlotinib 
(Tarceva®), cetuximab, bortezomib (Velcade®), panitu-
mumab (Vectibix®), vandetanib (ZD6474; Zactima®), and 
bevacizumab (Avastin®), into docetaxel-based regimens 
are currently underway (Table 4). The results from these 
clinical trials are eagerly anticipated and are predicted to 
improve outcomes in patients with SCCHN in both the LA 
and recurrent or metastatic setting.
Conclusions
Docetaxel is an agent with proven activity in the treatment 
of SCCHN. The pivotal TAX 323 and TAX 324 studies 
have recently established TPF as the most effective combi-
nation regimen for ICT, if the latter is chosen as the basis 
of a multidisciplinary program for the treatment of LA 
SCCHN. Future directions for docetaxel-based therapies 
include combination with other chemotherapeutic agents 
and novel biologic therapies – most notably agents targeted 
against the EGFR – and modiﬁ  cation of CCRT regimens. 
As an increasing number of targeted therapies become 
available for clinical trials (and eventually at the practicing 
oncologist’s ofﬁ  ce), we can hope to see more active com-
binations in SCCHN; indeed, there may be added beneﬁ  t 
from using such combinations as part of ICT regimens, 
integrated into the RT part of the sequential therapy regi-
men, or even as maintenance after the successful delivery 
of the local/regional component of the regimen (in com-
plete responders). There is currently a paucity of data on 
molecular endpoints that would be of prognostic and/or 
predictive value relevant to the use of TPF; such data 
could help stratify patients (according to disease site, stage, 
human papilloma virus tissue typing status, for example) 
who would beneﬁ  t from induction therapy vs those who 
may not. Secondary analysis of existing study data (eg, 
TAX 324) may provide some insight in this regard, but 
future studies should include appropriate endpoints to be 
prospectively investigated.
Promising results from ongoing studies with 
docetaxel-based treatments in SCCHN indicate that these 
regimens are poised to foster further improvement in patient 
outcomes, especially in LA disease, which has the potential 
to become a widely curable disease. Finally, reﬁ  nements in 
current treatment strategies incorporating docetaxel could 
increasingly prove clinical usefulness for the management of 
SCCHN in the metastatic or recurrent disease setting, which 
has been marred, historically, by poor outcomes.
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